Onyx spurns Amgen takeover bid, puts itself up for sale
This article was originally published in Scrip
Onyx Pharmaceuticals said it rejected Amgen’s unsolicited takeover offer for almost $9 billion and will seek out other companies that may be interested in acquiring the cancer drug specialist.
You may also be interested in...
Using Baxter’s Advate drug as a preventative therapy helped significantly reduce bleeding incidents in a yearlong study.
Mylan CEO Heather Bresch said she is looking to do a sizable deal that helps the US generic and specialty drug maker better compete in a consolidating field of rivals.
Biogen Idec CEO George Scangos is frank about his ambitions to dominate the market for hemophilia therapies, an opportunity he compares to the big biotech’s lead treating multiple sclerosis.